Invisible Disease

Hep Talk by Larry Buhl Organizations shine a light on HCV in jails and prisons The percentage of people chronically infected with hepatitis C (HCV) in...

HIV Latency & HDACs

Hide and Seek Led by Dr. Daria Hazuda, researchers tackle HIV latency with HDAC inhibitors by Chael Needle With all the talk around viral suppression, it may...

The Silent C

A new recommendation report provides a global look at hepatitis C Hep Talk by Larry Buhl There’s good news and bad news about the hepatitis C...

Skin Cancers Revisited

Sun Blocked A new study examines non-melanoma skin cancers & HIV by Chael Needle In the pre-HAART era, an AIDS diagnosis or even an HIV-positive diagnosis illuminated...

Bathroom Reading

A newly approved anti-diarrheal agent seeks to counter side effects of HAART by Chael Needle Recently, the FDA approved Fulyzaq (crofelemer) 125 mg delayed-release tablets for...

Year in Review

What were the top five HCV-related stories of 2012? by Larry Buhl There were many important news stories about hepatitis in 2012. In this column we...

Flipping the Script

Walgreens dispenses vital support through HIV-specialized pharmacies Wellness Watch by Chael Needle Individuals living with HIV/AIDS and in treatment may not know that one pharmacy may...

Starting the Conversation

HEPCredefined.com provides a portal for learning about HCV Hep Talk by Larry Buhl It’s been said that the hepatitis C virus (HCV) is a silent killer,...

Monoclonal Antibodies

Stronger Punch? Monoclonal antibodies provide new hope for easier dosing by Jeannie Wraight With multi-drug, once-a-day therapies now available for use, the push for additional easier to...

TB Announced

A not-for-profit biotech helps energize the future of TB vaccine R&D by Chael Needle According to the World Health Organization, tuberculosis is the most common illness...

LATEST POSTS

In Memoriam: Larry Pettit, 1945-2018

Late night on November 7, 2018, a massive heart attack took from us Larry Pettit, one of San Francisco’s LGBTQ community’s most beloved “characters”...

John Wikiera: Advocate

PrEP Factors